Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 19/20 | 0.39 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 0.39 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25338709 | 1.00 | MAP4K1 (0.39) | MAP4K1MAP4K3PSMB5 | |
| SCHEMBL25322498 | 0.81 | CYP1A2 (0.40) | — | |
| SCHEMBL25322497 | 0.81 | CYP1A2 (0.40) | — | |
| SCHEMBL30551027 | 0.81 | CYP1A2 (0.40) | — | |
| SCHEMBL30469859 | 0.81 | MAP4K1 (0.36) | MAP4K1MAP4K3 | |
| SCHEMBL24364988 | 0.81 | MAP4K1 (0.36) | MAP4K1MAP4K3 | |
| SCHEMBL29081354 | 0.80 | MAP4K1 (0.36) | MAP4K1MAP4K3 | |
| SCHEMBL30469845 | 0.80 | MAP4K1 (0.36) | MAP4K1MAP4K3 | |
| SCHEMBL24365030 | 0.80 | MAP4K1 (0.36) | MAP4K1MAP4K3 | |
| SCHEMBL25321555 | 0.79 | MAP4K1 (0.38) | MAP4K1MAP4K3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171432-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-05-29 | — | — | US | disclosed |
| WO-2023146989-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171432-A1 | COMPOUNDS AND METHODS OF USE | ABCG2, F12, CYP2C9 | MAP4K1 4460/4885MAP4K3 4363/4885PSMB5 3946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.